<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">NAT</journal-id><journal-title-group><journal-title>Hans Journal of Nanotechnology</journal-title></journal-title-group><issn pub-type="epub">2161-086X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/NAT.2021.113005</article-id><article-id pub-id-type="publisher-id">NAT-43975</article-id><article-categories><subj-group subj-group-type="heading"><subject>NAT20210300000_26178716.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>化学与材料</subject></subj-group></article-categories><title-group><article-title>
 
 
  红细胞改造作为药物载体研究进展
   Advances in Reformed Erythrocytes as Drug Deliver System
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>超</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>冯</surname><given-names>灵子</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>佳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>鲍</surname><given-names>鸿一</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>夏</surname><given-names>栋林</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>南通大学公共卫生学院，江苏 南通</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>28</day><month>06</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>36</fpage><lpage>42</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   红细胞作为人体循环系统内数目最多的细胞，具有生物安全性高、免疫源性低、柔韧性强、系统循环长、药物负载量高等特点，可解决当前传统药物输送体系面临的许多挑战性问题，故而被广泛研究。目前红细胞修饰作为药物递送载体已形成了多种成熟、可行的方法，主要可分为：基因修饰的红细胞载体、非基因修饰的红细胞载体和红细胞膜修饰纳米颗粒。本文综述了红细胞作为纳米药物载体的概况及研究进展，总结了红细胞改造的研究成果，并展望了红细胞药物递送系统的发展趋势。
    Erythrocytes, the most abundant cell type in the human body, are high bio-safety, hypoimmunogenic, flexibility, long cycling, and high drug loading. It was extensively studied as it can overcome many challenges in current conventional drug delivery systems. Up to now, there are many mature and feasible methods in reforming erythrocytes as drug carriers, which are mainly divided into the gene modification of erythrocytes, non-gene modification of erythrocytes and erythrocyte membrane modification of nano particles. This review focuses on the latest research progress on the reformed erythrocytes as drug nanocarriers. We also summarized the primary findings of reformed erythrocytes and outlooked future developing trends in reformed erythrocytes drug delivery system. 
  
 
</p></abstract><kwd-group><kwd>药物递送体系，红细胞，纳米颗粒，细胞膜修饰,  Drug Delivery System</kwd><kwd> Erythrocyte</kwd><kwd> Nanopar-ticles</kwd><kwd> Reformed Membrane</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>红细胞作为人体循环系统内数目最多的细胞，具有生物安全性高、免疫源性低、柔韧性强、系统循环长、药物负载量高等特点，可解决当前传统药物输送体系面临的许多挑战性问题，故而被广泛研究。目前红细胞修饰作为药物递送载体已形成了多种成熟、可行的方法，主要可分为：基因修饰的红细胞载体、非基因修饰的红细胞载体和红细胞膜修饰纳米颗粒。本文综述了红细胞作为纳米药物载体的概况及研究进展，总结了红细胞改造的研究成果，并展望了红细胞药物递送系统的发展趋势。</p></sec><sec id="s2"><title>关键词</title><p>药物递送体系，红细胞，纳米颗粒，细胞膜修饰</p></sec><sec id="s3"><title>Advances in Reformed Erythrocytes as Drug Deliver System<sup> </sup></title><p>Chao Chen, Lingzi Feng, Jia Li, Hongyi Bao, Donglin Xia<sup>*</sup></p><p>School of Public Health, Nantong University, Nantong Jiangsu</p><p><img src="//html.hanspub.org/file/2-1290132x5_hanspub.png?20210721083104596" /></p><p>Received: May 28<sup>th</sup>, 2021; accepted: Jul. 14<sup>th</sup>, 2021; published: Jul. 20<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/2-1290132x6_hanspub.png?20210721083104596" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Erythrocytes, the most abundant cell type in the human body, are high bio-safety, hypoimmunogenic, flexibility, long cycling, and high drug loading. It was extensively studied as it can overcome many challenges in current conventional drug delivery systems. Up to now, there are many mature and feasible methods in reforming erythrocytes as drug carriers, which are mainly divided into the gene modification of erythrocytes, non-gene modification of erythrocytes and erythrocyte membrane modification of nano particles. This review focuses on the latest research progress on the reformed erythrocytes as drug nanocarriers. We also summarized the primary findings of reformed erythrocytes and outlooked future developing trends in reformed erythrocytes drug delivery system.</p><p>Keywords:Drug Delivery System, Erythrocyte, Nanoparticles, Reformed Membrane</p><disp-formula id="hanspub.43975-formula17"><graphic xlink:href="//html.hanspub.org/file/2-1290132x7_hanspub.png?20210721083104596"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-1290132x8_hanspub.png?20210721083104596" /> <img src="//html.hanspub.org/file/2-1290132x9_hanspub.png?20210721083104596" /></p></sec><sec id="s5"><title>1. 引言</title><p>红细胞是人体循环体系中数量占比最大的血细胞，其主要承担人体各器官组织的氧气供应。与其他血细胞不同，红细胞缺乏细胞核且具有出色的柔韧性，可以使其改变形状以适应人体血管 [<xref ref-type="bibr" rid="hanspub.43975-ref1">1</xref>]。红细胞表面覆盖的关键蛋白标记使红细胞可以在体内长时间循环(在人体内约120天，在小鼠体内约50天)，而不会被巨噬细胞清除 [<xref ref-type="bibr" rid="hanspub.43975-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.43975-ref3">3</xref>]，这个独特的优势，使其能够携带治疗药物，改善药代动力学，改变药效并且能调节免疫反应。红细胞膜可以防止被包裹的药物被快速清除，从而实现药物在体内的长循环和持续释放 [<xref ref-type="bibr" rid="hanspub.43975-ref4">4</xref>]。成熟的红细胞不包含任何遗传物质，因此与其他基因和细胞疗法相比，其安全风险较小 [<xref ref-type="bibr" rid="hanspub.43975-ref5">5</xref>]。同时红细胞数目多、体内循环时间长、载药量高、生物相容性高，因此是体内药物递送的理想候选载体 [<xref ref-type="bibr" rid="hanspub.43975-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.43975-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.43975-ref8">8</xref>]。</p><p>基于红细胞的这些固有特性，多种红细胞药物递送平台的药物递送策略被开发。此外，许多研究还设计出了红细胞膜修饰纳米级颗粒，成为载有药物的红细胞。红细胞载体和红细胞膜包覆的纳米载体，均是基于红细胞的药物递送体系，由于红细胞表面修饰与功能化技术的快速发展，这些药物递送体系已从被动载体递送逐渐转变为主动载体递送 [<xref ref-type="bibr" rid="hanspub.43975-ref9">9</xref>]。</p></sec><sec id="s6"><title>2. 基于基因修饰方法的红细胞药物递送体系</title><p>基于基因修饰方法的红细胞药物递送核心是一种在未成熟的红细胞前体基因组中插入或替换新的基因以诱导基因表达且在红细胞内产生所需药物(主要是蛋白质与肽类药物)从而达到红细胞药物负载并实现治疗目的的方法 [<xref ref-type="bibr" rid="hanspub.43975-ref10">10</xref>]。红细胞表达治疗蛋白的基因工程方法已被广泛开发并商业化用于治疗各种疾病。红细胞核的缺乏限制了它们在成熟阶段的遗传修饰，因此，应对这一问题的另一种方法就是红细胞前体的基因修饰，以便在成熟的红细胞上表达蛋白质。Rubius Therapeutics是由FlagshipVentureLabs&#174;建立和启动的基于红细胞的商业化技术平台，该平台通过遗传修饰造血干细胞，从而使最终功能性红细胞(Red-Cell Therapeutics<sup>TM</sup>)可以在细胞表面或细胞溶胶中呈现多种治疗性蛋白质用来治疗包含了癌症、自身免疫性疾病和其他罕见疾病在内的多种疾病。这些通过基因修饰并表达产生的治疗性蛋白质包括受体激动剂、抗原结合剂、酶及他们的组合。另一项研究是通过对红细胞的前体进行基因工程改造，产生了一种在膜上表达分选酶的红细胞。</p><p>最近的另外一项研究展示了一种采用逆转录病毒对红细胞进行基因修饰的方法，以单域抗体(VHH)对造血干细胞和祖细胞(HSPC)等红细胞前体进行遗传修饰来实现对A型肉毒杆菌神经毒素(BoNT/A)解毒的作用(A型肉毒杆菌神经毒素是一种神经元毒素，会导致松弛性麻痹和死亡)。其中基于VHHs的A型中和剂(VNA/A)专门识别和中和BoNT/A，能够达到解毒效果。糖蛋白A(GPA)和锌蛋白酶(Kell)在HSPC和成熟的红细胞上均有表达，这使其成为适合修饰的靶标。通过在鼠糖蛋白A(GPA)的N'端和Kell的C'端将编码嵌合蛋白的病毒载体与VNA融合，产生具备能够在细胞膜表面表达GPA-VNA和Kell-VNA蛋白的红细胞。在动物实验中，骨髓重建后的小鼠中，顺利产生GPA-VNA/A和Kell-VNA/A的小鼠都在每周剂量逐渐增加的BoNT/A感染中生存下来。即便使用BoNT/A的致命剂量(LD<sub>50</sub>)的10,000倍进行处理后，两组小鼠仍然能存活下来。这些由基因工程编辑的红细胞输注到幼年小鼠的体内可提供长达28天的抗毒素能力 [<xref ref-type="bibr" rid="hanspub.43975-ref11">11</xref>]。</p><p>为了解决血液的来源问题，使用了CRISPR/Cas9在Kell蛋白的C'末端将LPETGG基序引入小鼠体内，这样产生的Kell-LPETGG小鼠将作为红细胞的采集主体。将经过修饰的红细胞与相关的自身抗原通过静脉输注方式进入小鼠体内可缓解自身免疫性脑脊髓炎(EAE)的病理症状。</p><p>对于基因修饰红细胞来说，大多做法都是从不成熟的HSPC(祖细胞)入手，这样对于修饰的红细胞来说，影响较小。与正常成熟的红细胞相比，从细胞大小、表面蛋白表达和血红蛋白含量上进行比较，针对HSPC的基因修饰可使生成的红细胞的生物性状变化降至最低。通过以上方法能够提供安全的接近正常原生状态的红细胞，因此在临床上，这个技术也已经被投入使用 [<xref ref-type="bibr" rid="hanspub.43975-ref12">12</xref>]。此外，由于所有人类成熟红细胞都没有细胞核，也没有任何遗传物质，因此最终的无基因红细胞可能更加安全。同时相比于其他基因细胞疗法(如CAR-T疗法或干细胞疗法)更容易控制。</p></sec><sec id="s7"><title>3. 基于非基因修饰方法的红细胞药物递送体系</title><p>对基于非基因修饰方法的红细胞药物递送体系而言，药物的装载成为首先需要攻克的难点。目前已经开发出了多种策略来为红细胞加载药物，包括电脉冲、低渗预溶胀、低渗透析、低渗稀释、渗透脉冲/等渗溶血、细胞穿透肽(CPP)和红细胞加载器技术 [<xref ref-type="bibr" rid="hanspub.43975-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.43975-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.43975-ref15">15</xref>]。</p><p>其中最简单的方法是将粒子非特异性地物理吸附到红细胞表面。与其他细胞类似，红细胞的细胞膜包含相对疏水的区域，该区域包含了能够结合疏水颗粒的位点。这些可结合疏水颗粒位点与疏水微粒之间的相互作用已被证明与电荷无关，因为带正电和带负电的疏水性颗粒均能与红细胞膜结合 [<xref ref-type="bibr" rid="hanspub.43975-ref16">16</xref>]。一些其他的例子中，阳离子颗粒可以结合到红细胞的糖蛋白上 [<xref ref-type="bibr" rid="hanspub.43975-ref17">17</xref>]，而具有硅醇官能团的中孔二氧化硅纳米颗粒能够通过与红细胞膜上存在的磷脂酰胆碱相互作用而吸附到红细胞上 [<xref ref-type="bibr" rid="hanspub.43975-ref18">18</xref>]。</p><p>除了红细胞的内部空间外，红细胞的较大的表面积体积比也有利于药物表面吸附或是依赖化学键修饰。通过静电相互作用，范德华力和/或疏水相互作用，纳米颗粒可以附着在红细胞表面上 [<xref ref-type="bibr" rid="hanspub.43975-ref6">6</xref>]。</p><p>通过附着在红细胞表面，220 nm聚苯乙烯纳米颗粒的血管循环时间可显着增加到原来的100倍以上，这种装载策略被证实对于直径范围从100 nm到1.1 μm的纳米颗粒是有效的 [<xref ref-type="bibr" rid="hanspub.43975-ref19">19</xref>]。据Anselmo [<xref ref-type="bibr" rid="hanspub.43975-ref1">1</xref>] 等人的发现：将聚苯乙烯纳米颗粒搭载到红细胞的表面上，可以实现更长的保留时间和约7倍的肺部积聚浓度。这种红细胞细胞表面搭载策略解决了基于纳米粒子的治疗策略中的两个主要问题：避免代谢器官(如肝脏和脾脏)的清除和纳米粒子难以到达的部位(如肺和脑)的富集，这为纳米粒子的递送提供了一种新方法，该策略近年来在控释载药体系的设计中的被广泛应用。</p><p>除了物理附着，生物分子还可以通过共价结合与红细胞的外部连接。生物素–亲和素链接是也是常见的在红细胞表面装载药物的策略。Tat抗原是一种人免疫缺陷病毒(HIV)调节蛋白，可以通过生物素–亲和素链接有效地与红细胞结合。事实证明，利用红细胞-Tat将抗原递送至DC，从而产生Tat特异性抗原CD4+和抗原CD8+T细胞是Tat用于产生HIV特异性免疫的一种好方法 [<xref ref-type="bibr" rid="hanspub.43975-ref20">20</xref>]。在另一项工作中成功地偶联了抗原肽(OVA257-264，SIINFEKL)，并将主要的组织相容性复合物I (pMHC-1)和抗CD28抗体涂在红细胞的表面上，通过生物素–亲和素链接方式获得人工抗原呈递细胞，再通过DSPE-PEG-抗His抗体复合物将获得的人工抗原呈递细胞(aAPC)进一步与白介素2 (IL-2)以T细胞增殖信号的形式联系在一起，从而成功模拟旁分泌激活途径。当在体外与脾细胞一起孵育时，此类aAPC-IL2显示出较强的CD8+T细胞活化功能，能够触发T细胞增殖显着增强和炎性细胞因子分泌增加。这些活化的脾细胞可以通过特异性抗原方式有效地破坏癌细胞，因此，这表明了这种基于红细胞的aAPC体系有望用于T细胞的活化。该策略可能是体外间接促进T细胞转移的潜在且有前途的方法 [<xref ref-type="bibr" rid="hanspub.43975-ref21">21</xref>]。</p><p>因此，具有一系列理想特性的红细胞可以作为药物输送体系的负载细胞，可以通过不同的离体方法将药物装载到红细胞内部或外部膜上，这些载体红细胞将是多种药物的安全载体。</p></sec><sec id="s8"><title>4. 红细胞膜修饰的纳米颗粒药物输送体系</title><p>受红细胞出色性能的启发，研究人员设计了具有类似红细胞膜化学特性和生物学功能的药物载体，这些药物载体利用其表面包覆的红细胞膜可成功伪装成血液中的红细胞：</p><p>一种策略是用红细胞膜制备纳米大小的囊泡，这种方法依赖一系列的膜挤出设备来制得。Lejeuen等人 [<xref ref-type="bibr" rid="hanspub.43975-ref22">22</xref>] 首先通过膜挤压法制备了纳米尺寸的红细胞囊泡。根据他们的结果，红细胞膜通过0.4 μm和1 μm的孔挤出均产生了平均直径为0.1 μm的纳米级红细胞囊泡。正常红细胞微米级别尺寸限制了其向血管外部扩散的能力，因此粒径更小的纳米级红细胞膜囊泡将很好的解决这个问题。小尺寸使红细胞囊泡能够穿透某些组织并最终达到细胞内以进行药物输送。</p><p>红细胞膜包裹的全氟化碳纳米乳液具有极高的携氧能力，近期一篇报道中，构建了一种基于纳米电机的输送体系，该纳米电机结合了超声场下金纳米电机(AuNW)的快速推进能力和红细胞包裹的全氟化碳高携氧能力，能够实现主动的细胞内氧气输送 [<xref ref-type="bibr" rid="hanspub.43975-ref23">23</xref>]。</p><p>由于具有自标记蛋白，红细胞膜具有完美的生物相容性和免疫逃避能力的隐身“涂层伪装” [<xref ref-type="bibr" rid="hanspub.43975-ref2">2</xref>]。根据先前的研究，证实了用于包被纳米颗粒的红细胞膜上抗原CD47的密度与天然红细胞膜相当 [<xref ref-type="bibr" rid="hanspub.43975-ref3">3</xref>]。最近一种在PLGA内封装全氧化碳(PFC)的纳米级红细胞模拟体系被开发出来，这是一种具有极高的氧溶解度的人造血液替代品，这些粒子进一步被红细胞膜伪装，合成了PFC@PLGA-RBCM纳米粒子。该纳米粒子在静脉注射24小时后，对小鼠进行了8 Gy剂量的放疗，结果显示接受PFC@PLGA-RBCM注射的小鼠配合放疗后显示出比不接受注射小鼠对肿瘤生长的更强的抑制作用。这可能是由于溶解氧的PFC减轻了肿瘤微环境中的缺氧，大大提高了RT期间的治疗效果 [<xref ref-type="bibr" rid="hanspub.43975-ref24">24</xref>]。</p><p>尽管红细胞膜包被的纳米颗粒的循环时间长，但是目标选择性也是将红细胞膜包被的纳米颗粒用于疾病治疗，尤其是在癌症治疗中的重要特性。据先前的研究，采用脂质插入技术制备具有靶向能力的红细胞膜包被的纳米颗粒在体外具有出色的靶向能力。该纳米颗粒是通过将叶酸-PEG-脂质缀合物或核仁素靶向的适体AS1411插入红细胞膜空壳中，然后将红细胞膜包裹住药物核心合成的 [<xref ref-type="bibr" rid="hanspub.43975-ref25">25</xref>]。</p><p>上转换纳米粒子(UCNPs)具有优异的光学和化学特性，被广泛应用于体内肿瘤成像，然而UCNPs在生物液体中会自动覆盖靶向配体，将大大降低纳米粒子靶向能力。通过在UCNPs表面覆盖红细胞膜以避免其表面靶向配体的聚集，这能够避免靶向能力的减弱，这对使用UCNPs进行增强体内成像产生了极大帮助 [<xref ref-type="bibr" rid="hanspub.43975-ref26">26</xref>]。</p><p>光热疗法是一种仅由肿瘤部位光信号引发的温度升高来移除癌细胞的疗法，最近一篇报道提出将光催化剂二氧化钛胶体和光热试剂纳米金(AuNRs)包裹在红细胞膜囊泡中制备光信号激活肿瘤治疗的仿生纳米胶囊的方案。制备的Au/TiO<sub>2</sub>@RBC纳米胶囊在其表面细胞膜涂层的光催化降解过程中可以实现对AuNRs的控制释放，释放出的AuNRs经近红外激光照射后产生治疗效果。同时，光催化产生的活性氧(ROS)有助于光动力杀灭肿瘤细胞 [<xref ref-type="bibr" rid="hanspub.43975-ref27">27</xref>]。</p><p>使用红细胞膜包裹磁性纳米团簇可用于双峰成像引导癌症光热治疗。通过使用血影细胞膜包裹超顺磁性的纳米团簇(MNC)形成Cyp-MNC@RBCs微粒，该微粒暴露在近红外激光下(NIR)后，表现出明显的近红外吸收和高效光热转换效率。同时静脉注射的Cyp-MNC@RBC具有一定的肿瘤富集能力，因此该纳米粒子能够作为荧光与核磁共振成像(MRI)双峰成像并用于应道肿瘤光热治疗 [<xref ref-type="bibr" rid="hanspub.43975-ref28">28</xref>]。</p><p>红细胞大多用来递送亲水的溶质，与装载亲水分子不同，分子主要包在在亲脂的外壳内。最近一篇报道使用红细胞膜提取的纳米微囊成功负载疏水药物喜树碱(CPT)，在动物实验中，经过静脉注射的纳米粒子在血液中滞留时间超过48小时，同时在主要脏器中的蓄积并不明显。因此红细胞在亲脂药物递送中也具有应用潜力 [<xref ref-type="bibr" rid="hanspub.43975-ref29">29</xref>]。</p><p>综上所述，修饰后的红细胞膜涂层可以实现细胞膜涂覆的纳米粒子的特异性靶向。在纳米颗粒用于疾病治疗中时，红细胞膜的特异性靶向是相当有意义的，这有望使得那些靶向性不强的药物在使用过程中副作用最小化。大多数情况下，这种靶向作用是通过用于疾病部位过度表达的抗原结合的配体官能化纳米颗粒来实现的，目前已经采用了多种基于羧基、胺基或巯基的化学偶联技术来修饰这些配体的合成纳米颗粒 [<xref ref-type="bibr" rid="hanspub.43975-ref30">30</xref>] [<xref ref-type="bibr" rid="hanspub.43975-ref31">31</xref>]。靶向纳米粒子已经被证明在靶点位置优先累积，并已在临床研究中产生令人欣慰的治疗效果 [<xref ref-type="bibr" rid="hanspub.43975-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.43975-ref32">32</xref>] [<xref ref-type="bibr" rid="hanspub.43975-ref33">33</xref>]。</p><p>但是，在红细胞膜包被纳米颗粒的情况下，颗粒表面生物活性成分是有要求的。因为红细胞膜的免疫逃逸能力取决于膜表面是否具有完全功能的用于免疫逃逸的蛋白质。脂质插入方法能够有效避免表面蛋白质潜在的化学变性，该方法首先将靶向部分束缚到脂质分子上，然后插入到红细胞膜上 [<xref ref-type="bibr" rid="hanspub.43975-ref34">34</xref>]。插入是一个物理过程，通过双层膜的固有流动性和动态构象实现。在不损坏现有表面蛋白的情况下，将大小不同的配体（包括叶酸等小分子和核仁蛋白靶向的适体AS1411等大分子）插入红细胞膜。此外，通过此策略，可以轻松控制配体密度，从而实现了红细胞膜的多功能性。</p></sec><sec id="s9"><title>5. 展望</title><p>修饰红细胞或使用红细胞膜制备囊泡和颗粒的最终目标是有效地运送药物，同时保持其表面特征用以逃避免疫系统的侦测并引起最小的有害免疫反应 [<xref ref-type="bibr" rid="hanspub.43975-ref35">35</xref>]。因此，有必要在临床使用前测试其体内性能。在该领域中，大多数临床前研究都是在小型动物中进行的，在进行人类测试之前，还需要在大型动物中进行进一步的实验。另一个问题可能是血液供应，在小型动物实验中，均是从同系动物模型收集的全血以避免有害的免疫原性反应。为了进一步的临床使用，修饰过的红细胞或红细胞衍生的载体体系应与患者的血型和Rh相容性相匹配 [<xref ref-type="bibr" rid="hanspub.43975-ref36">36</xref>]。</p><p>然而，红细胞膜上的外来分子的修饰或多或少会诱导同种免疫，这在临床使用中是潜在的风险，尤其是在重复给药后。据信同种免疫的程度与细胞表面修饰分子的密度有关。全身性施用外源蛋白质还增加了诱导强烈抗体反应的显着风险。另外，尽管与裸露的纳米颗粒相比，用红细胞膜涂覆的纳米颗粒表现出更长的保留时间，但是这种纳米颗粒的保留时间仍然比红细胞本身短得多。因此，有必要在包覆后对膜的性能进行测试 [<xref ref-type="bibr" rid="hanspub.43975-ref37">37</xref>]。同时，虽然已经成功开发了多种策略将药物装载到红细胞中，但是，这些方法会造成膜损伤，从而导致结构完整性丧失和渗透压变化，使它们易于被宿主免疫系统识别和清除 [<xref ref-type="bibr" rid="hanspub.43975-ref38">38</xref>]。与其他基于细胞或细胞膜的治疗策略相比，基于红细胞的药物递送体系很难实现局部释放(除了RES靶向之外)，这限制了其潜在的应用范围 [<xref ref-type="bibr" rid="hanspub.43975-ref7">7</xref>]。</p><p>尽管大多数基于红细胞的药物输送体系仍处于概念验证阶段，但一些已在临床前研究中被证明是有效和安全的，并且有望成为有前途的临床治疗方法。</p></sec><sec id="s10"><title>基金项目</title><p>感谢南通市科技局基础科学研究项目(JC2019139)的支持。</p></sec><sec id="s11"><title>文章引用</title><p>陈 超,冯灵子,李 佳,鲍鸿一,夏栋林. 红细胞改造作为药物载体研究进展 Advances in Reformed Erythrocytes as Drug Deliver System[J]. 纳米技术, 2021, 11(03): 36-42. https://doi.org/10.12677/NAT.2021.113005</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43975-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Wu, S.H., Hsieh, C.C., Hsu, S.C., et al. (2021) RBC-Derived Vesicles as a Systemic Delivery System of Doxorubicin for Lysosomal-Mitochondrial Axis-Improved Cancer Therapy. Journal of Advanced Research, 30, 185-196.  
&lt;br&gt;https://doi.org/10.1016/j.jare.2020.11.009</mixed-citation></ref><ref id="hanspub.43975-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Kim, M.W., Lee, G., Niidome, T., et al. (2020) Platelet-Like Gold Nanostars for Cancer Therapy: The Ability to Treat Cancer and Evade Immune Reactions. Frontiers in Bioengineering and Biotechnology, 8, 133.  
&lt;br&gt;https://doi.org/10.3389/fbioe.2020.00133</mixed-citation></ref><ref id="hanspub.43975-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y., Zhou, C., Ding, Y., et al. (2021) Red Blood Cell-Hitchhiking Chitosan Nanoparticles for Prolonged Blood Circulation Time of Vitamin K1. International Journal of Pharmaceutics, 592, Article ID: 120084.  
&lt;br&gt;https://doi.org/10.1016/j.ijpharm.2020.120084</mixed-citation></ref><ref id="hanspub.43975-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Rossi, L., Pierigè, F., Antonelli, A., et al. (2016) Engineering Erythrocytes for the Modulation of Drugs’ and Contrasting Agents’ Pharmacokinetics and Biodistribution. Advanced Drug Delivery Reviews, 106, 73-87.  
&lt;br&gt;https://doi.org/10.1016/j.addr.2016.05.008</mixed-citation></ref><ref id="hanspub.43975-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Singh, M.P., Flynn, N.H., Sethuraman, S.N., et al. (2021) Repro-gramming the Rapid Clearance of Thrombolytics by Nanoparticle Encapsulation and Anchoring to Circulating Red Blood Cells. The Journal of Controlled Release, 329, 148-161. &lt;br&gt;https://doi.org/10.1016/j.jconrel.2020.11.034</mixed-citation></ref><ref id="hanspub.43975-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Tan, S., Wu, T., Zhang, D., et al. (2019) Cell or Cell Membrane-Based Drug Delivery Systems. Theranostics, 5, 863-863. &lt;br&gt;https://doi.org/10.7150/thno.11852</mixed-citation></ref><ref id="hanspub.43975-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Zelepukin, I.V., Yaremenko, A.V., Shipunova, V.O., et al. (2019) Nano-particle-Based Drug Delivery via RBC-Hitchhiking for the Inhibition of Lung Metastases Growth. Nanoscale, 11, 1636-1646. &lt;br&gt;https://doi.org/10.1039/C8NR07730D</mixed-citation></ref><ref id="hanspub.43975-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Li, C., Wang, X., Li, R., et al. (2019) Resveratrol-Loaded PLGA Nanoparticles Functionalized with Red Blood Cell Membranes as a Biomimetic Delivery System for Prolonged Circulation Time. Journal of Drug Delivery Science and Technology, 54, Article ID: 101369. &lt;br&gt;https://doi.org/10.1016/j.jddst.2019.101369</mixed-citation></ref><ref id="hanspub.43975-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Luk, B.T. and Zhang, L. (2015) Cell Membrane-Camouflaged Nanoparticles for Drug Delivery. Journal of Controlled Release, 220, 600-607. &lt;br&gt;https://doi.org/10.1016/j.jconrel.2015.07.019</mixed-citation></ref><ref id="hanspub.43975-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Maeder, M.L. and Gersbach, C.A. (2016) Genome-Editing Technologies for Gene and Cell Therapy. Molecular Therapy, 24, 430-446. &lt;br&gt;https://doi.org/10.1038/mt.2016.10</mixed-citation></ref><ref id="hanspub.43975-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Huang, N.J., Pishesha, N., Mukherjee, J., et al. (2017) Genetically Engi-neered Red Cells Expressing Single Domain Camelid Antibodies Confer Long-Term Protection against Botulinum Neu-rotoxin. Nature Communications, 8, 423.  
&lt;br&gt;https://doi.org/10.1038/s41467-017-00448-0</mixed-citation></ref><ref id="hanspub.43975-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">杨根生, 金陈浩, 徐书敏, 等. 红细胞药物递送系统的研究进展[J]. 浙江工业大学学报, 2020, 48(6): 684-689.</mixed-citation></ref><ref id="hanspub.43975-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Sun, X., Wang, C., Gao, M., et al. (2015) Remotely Con-trolled Red Blood Cell Carriers for Cancer Targeting and Near-Infrared Light-Triggered Drug Release in Combined Pho-tothermal-Chemotherapy. Advanced Functional Materials, 25, 2386-2394. &lt;br&gt;https://doi.org/10.1002/adfm.201500061</mixed-citation></ref><ref id="hanspub.43975-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Xu, Q., Wan, J., Bie, N., et al. (2018) A Biomimetic Gold Nanocag-es-Based Nanoplatform for Efficient Tumor Ablation and Reduced Inflammation. Theranostics, 8, 5362-5362. &lt;br&gt;https://doi.org/10.7150/thno.27631</mixed-citation></ref><ref id="hanspub.43975-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Villa, C.H., Anselmo, A.C., Mitragotri, S., et al. (2016) Red Blood Cells: Supercarriers for Drugs, Biologicals, and Nanoparticles and Inspiration for Advanced Delivery Systems. Advanced Drug Delivery Reviews, 106, 88-103.  
&lt;br&gt;https://doi.org/10.1016/j.addr.2016.02.007</mixed-citation></ref><ref id="hanspub.43975-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, R., Avsievich, T., Popov, A., et al. (2021) In Vivo Nano-Biosensing Element of Red Blood Cell-Mediated Delivery. Biosensors and Bioelectronics, 175, Article ID: 112845. &lt;br&gt;https://doi.org/10.1016/j.bios.2020.112845</mixed-citation></ref><ref id="hanspub.43975-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Mai, T.D., d’Orlyé, F., Ménager, C., et al. (2013) Red Blood Cells Decorated with Functionalized Core-Shell Magnetic Nanoparticles: Elucidation of the Adsorption Mechanism. Chemical Communications, 49, 5393-5395.  
&lt;br&gt;https://doi.org/10.1039/c3cc41513a</mixed-citation></ref><ref id="hanspub.43975-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, Y., Sun, X., Zhang, G., et al. (2011) Interaction of Mesoporous Silica Nanoparticles with Human Red Blood Cell Membranes: Size and Surface Effects. ACS Nano, 5, 1366-1375. &lt;br&gt;https://doi.org/10.1021/nn103077k</mixed-citation></ref><ref id="hanspub.43975-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Chambers, E. and Mitragotri, S. (2007) Long Circulating Nanoparticles via Adhesion on Red Blood Cells: Mechanism and Extended Circulation. Experimental Biology and Medicine, 232, 958-966.</mixed-citation></ref><ref id="hanspub.43975-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">李诗浩, 张麟. 红细胞膜封装负载姜黄素的金纳米粒子[J]. 精细化工, 2020, 37(9): 97-102.</mixed-citation></ref><ref id="hanspub.43975-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Sun, X., Han, X., Xu, L., et al. (2017) Surface-Engineering of Red Blood Cells as Artificial Antigen Pre-senting Cells Promising for Cancer Immunotherapy. Small, 13, Article ID: 1701864. &lt;br&gt;https://doi.org/10.1002/smll.201701864</mixed-citation></ref><ref id="hanspub.43975-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Wang, C., Ye, Y., Sun, W., et al. (2017) Red Blood Cells for Glu-cose-Responsive Insulin Delivery. Advanced Materials, 29, Article ID: 1606617. &lt;br&gt;https://doi.org/10.1002/adma.201606617</mixed-citation></ref><ref id="hanspub.43975-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, F.Y., Zhuang, J., Esteban, F., Ávila, B., et al. (2019) A Na-nomotor-Based Active Delivery System for Intracellular Oxygen Transport. ACS Nano, 13, 11996-12005. &lt;br&gt;https://doi.org/10.1021/acsnano.9b06127</mixed-citation></ref><ref id="hanspub.43975-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Gao, M., Liang, C., Song, X., et al. (2017) Erythro-cyte-Membrane-Enveloped Perfluorocarbon as Nanoscale Artificial Red Blood Cells to Relieve Tumor Hypoxia and En-hance Cancer Radiotherapy. Advanced Materials, 29, Article ID: 1701429. &lt;br&gt;https://doi.org/10.1002/adma.201701429</mixed-citation></ref><ref id="hanspub.43975-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Fang, R.H., Hu, C.M.J., Chen, K.N.H., et al. (2013) Lipid-Insertion Enables Targeting Functionalization of Erythrocyte Membrane-Cloaked Nanoparticle. Nanoscale, 5, 8884-8888. &lt;br&gt;https://doi.org/10.1039/c3nr03064d</mixed-citation></ref><ref id="hanspub.43975-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Rao, L., Meng, Q.F., Bu, L.L., et al. (2017) Erythrocyte Mem-brane-Coated Upconversion Nanoparticles with Minimal Protein Adsorption for Enhanced Tumor Imaging. ACS Applied Materials &amp; Interfaces, 9, 2159-2168.  
&lt;br&gt;https://doi.org/10.1021/acsami.6b14450</mixed-citation></ref><ref id="hanspub.43975-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Li, S.H. and Zhang, L. (2020) Erythrocyte Membrane Nano-Capsules: Biomimetic Delivery and Controlled Release of Photothermal-Photochemical Coupling Agents for Cancer Cell Therapy. Dalton Transactions, 49, 2645-2651.  
&lt;br&gt;https://doi.org/10.1039/C9DT04335G</mixed-citation></ref><ref id="hanspub.43975-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Wang, S., Yin, Y.P.C., Song, W., et al. (2020) Red-Blood-Cell-Membrane-Enveloped Magnetic Nanoclusters as a Biomimetic Theranostic Nanoplatform for Bimodal Imaging-Guided Cancer Photothermal Therapy. Journal of Materials Chemistry B, 8, 803-812. &lt;br&gt;https://doi.org/10.1039/C9TB01829H</mixed-citation></ref><ref id="hanspub.43975-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Malhotra, S., Dumoga, S., Sirohi, P., et al. (2019) Red Blood Cells-Derived Vesicles for Delivery of Lipophilic Drug Camptothecin. ACS Applied Materials &amp; Interfaces, 11, 22141-22151. &lt;br&gt;https://doi.org/10.1021/acsami.9b04827</mixed-citation></ref><ref id="hanspub.43975-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Gu, F., Zhang, L., Teply, B.A., et al. (2008) Precise Engineering of Targeted Nanoparticles by Using Self-Assembled Biointegrated Block Copolymers. Proceedings of the National Academy of Sciences of the United States of America, 105, 2586-2591. &lt;br&gt;https://doi.org/10.1073/pnas.0711714105</mixed-citation></ref><ref id="hanspub.43975-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Pridgen, E.M., Alexis, F., Kuo, T.T., et al. (2013) Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal fc Receptor for Oral Delivery. Science Translational Medicine, 5, 213ra167.  
&lt;br&gt;https://doi.org/10.1126/scitranslmed.3007049</mixed-citation></ref><ref id="hanspub.43975-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">万胜利, 杨刚, 叶云. 新型载体及新技术在治疗酶研究中的应用[J]. 中国生物医学工程学报, 2020(1): 114-118.</mixed-citation></ref><ref id="hanspub.43975-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Phan, A., Takimoto, C., Adinin, R., et al. (2017) Open La-bel Phase I Study of MBP-426, a Novel Formulation of Oxaliplatin, in Patients with Advanced or Metastatic Solid Tu-mors. Molecular Cancer Therapeutics, 6, 3563S-3564S.</mixed-citation></ref><ref id="hanspub.43975-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Davis, M.E., Zuckerman, J.E., Choi, C.H.J., et al. (2010) Evidence of RNAi in Humans from Systemically Administered siRNA via Targeted Nanoparticles. Nature, 464, 1067-1070. &lt;br&gt;https://doi.org/10.1038/nature08956</mixed-citation></ref><ref id="hanspub.43975-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Pierigè, F., Bigini, N., Rossi, L., et al. (2017) Reengineering Red Blood Cells for Cellular Therapeutics and Diagnostics. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobi-otechnology, 9, e1454.  
&lt;br&gt;https://doi.org/10.1002/wnan.1454</mixed-citation></ref><ref id="hanspub.43975-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Gao, W. and Zhang, L. (2015) Engineering Red-Blood-Cell-Membrane-Coated Nanoparticles for Broad Biomedical Applications. AIChE Journal, 61, 738-746. &lt;br&gt;https://doi.org/10.1002/aic.14735</mixed-citation></ref><ref id="hanspub.43975-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Shi, J., Kantoff, P.W., Wooster, R., et al. (2017) Cancer Nanomedicine: Progress, Challenges and Opportunities. Nature Reviews Cancer, 17, 20-21. &lt;br&gt;https://doi.org/10.1038/nrc.2016.108</mixed-citation></ref><ref id="hanspub.43975-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">He, H., Ye, J., Wang, Y., et al. (2014) Cell-Penetrating Peptides Medi-tated Encapsulation of Protein Therapeutics into Intact Red Blood Cells and Its Application. Journal of Controlled Re-lease, 176, 123-132.  
&lt;br&gt;https://doi.org/10.1016/j.jconrel.2013.12.019</mixed-citation></ref></ref-list></back></article>